Evidence map›Paper›PMID 36349272›Full record

ArticleChemical science2022

Design of an activatable NIR-II nanoprobe for the

Yi Lai, Yijing Dang, Qian Sun, Jiaxing Pan, Haijun Yu, Wen Zhang, Zhiai Xu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yi LaiSchool of Chemistry and Molecular Engineering, East China Normal University 500 Dongchuan Road Shanghai 200241 China wzhang@chem.ecnu.edu.cn zaxu@chem.ecnu.edu.cn.
Yijing DangSchool of Chemistry and Molecular Engineering, East China Normal University 500 Dongchuan Road Shanghai 200241 China wzhang@chem.ecnu.edu.cn zaxu@chem.ecnu.edu.cn.
Qian SunSchool of Chemistry and Molecular Engineering, East China Normal University 500 Dongchuan Road Shanghai 200241 China wzhang@chem.ecnu.edu.cn zaxu@chem.ecnu.edu.cn.
Jiaxing PanState Key Laboratory of Drug Research, Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China.
Haijun YuState Key Laboratory of Drug Research, Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China.ORCID https://orcid.org/0000-0002-3398-0880
Wen ZhangSchool of Chemistry and Molecular Engineering, East China Normal University 500 Dongchuan Road Shanghai 200241 China wzhang@chem.ecnu.edu.cn zaxu@chem.ecnu.edu.cn.ORCID https://orcid.org/0000-0001-7918-4065
Zhiai XuSchool of Chemistry and Molecular Engineering, East China Normal University 500 Dongchuan Road Shanghai 200241 China wzhang@chem.ecnu.edu.cn zaxu@chem.ecnu.edu.cn.ORCID https://orcid.org/0000-0002-4391-2507
East China Normal University · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear elucidation of the changes in Alzheimer's disease (AD)-related methylglyoxal (MGO) levels

Identifiers

PMID36349272
PMCPMC9628982
OpenAlexW4308683711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.